GlassScriptPhysician profile
Harrison W Torres
NPI 1871052209
$1,202.95
in general payments reported to CMS, 2019-2025
15 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $53.97 · 2024: $801 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,168 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.89 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $304.31 | 2024-2025 | Greenlight Xps, Axonics, Spaceoar Vue System - 10ml |
| Cook Medical LLC | $174.27 | 2024 | Cook |
| Medtronic, INC. | $110.28 | 2024-2025 | Interstim |
| Amgen INC. | $108.77 | 2025 | Repatha |
| C. R. Bard, INC. & Subsidiaries | $107.71 | 2024 | Bard Urinary Drainage Bag |
| Urogen Pharma, INC. | $66.19 | 2024-2025 | |
| Teleflex LLC | $64.22 | 2024-2025 | Barrigel, Urolift |
| Intuitive Surgical, INC. | $53.97 | 2023 | |
| Sumitomo Pharma America, INC. | $52.88 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Axonics, INC. | $33.30 | 2024 | Bulkamid, Axonics |
| Vertex Pharmaceuticals Incorporated | $25.22 | 2024 | |
| Endo USA, INC. | $24.51 | 2025 | Xiaflex, Aveed |
| Sobi, INC | $23.48 | 2024 | |
| Coloplast Corp | $18.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrison Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.